Home » Stocks » Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. (ENZN)

Stock Price: $0.200 USD 0.000 (0.00%)
Updated Aug 6, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 8.84M
Revenue (ttm) 61,000
Net Income (ttm) -1.07M
Shares Out 44.21M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend $0.12
Dividend Yield 60.00%

Stock Quote

Trading Day Aug 6, 2020
Last Price $0.200
Previous Close $0.200
Change ($) 0.000
Change (%) 0.00%
Day's Open 0.190
Day's Range 0.190 - 0.220
Day's Volume 77,683
52-Week Range 0.135 - 0.305

More Stats

Market Cap 8.84M
Enterprise Value 2.93M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.21M
Float 27.36M
EPS (basic) -0.03
EPS (diluted) -0.02
FCF / Share 0.18
Dividend $0.12
Dividend Yield 60.00%
Earnings Yield n/a
FCF Yield 88.75%
Payout Ratio n/a
Shares Short 157,472
Short Ratio 1.03
Short % of Float 0.41%
Beta 0.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 1.13
PS Ratio 144.97
PB Ratio 1.35
Revenue 61,000
Operating Income -1.06M
Net Income -1.07M
Free Cash Flow 7.85M
Net Cash 5.91M
Net Cash / Share 0.13
Gross Margin 339.34%
Operating Margin -1,736.07%
Profit Margin -1,745.90%
FCF Margin 12,865.57%
ROA -7.19%
ROE -12.15%
ROIC 153.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$16.00*
Low
16.0
Current: $0.200
High
16.0
Target: 16.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.216.928.388.3817.4631.1734.4942.6048.0797.87
Revenue Growth-97.01%-17.44%0.02%-52.01%-44%-9.63%-19.03%-11.38%-50.88%-
Gross Profit0.216.928.388.3817.4631.1734.4942.6048.0797.87
Operating Income-0.975.867.016.6410.8028.7918.16-3.97-16.46-0.58
Net Income-0.985.855.45-1.1321.6428.8018.15-2.78-20.76177
Shares Outstanding44.2244.2244.2244.2244.2044.1343.7846.7451.9158.47
Earnings Per Share-0.020.130.12-0.030.490.650.38-0.06-0.403.03
EPS Growth-8.33%---24.62%71.05%----
Dividend Per Share0.12-0.150.150.85-3.652.00--
Dividend Growth--0%-82.35%--82.5%---
Operating Cash Flow6.91-0.986.472.6014.6832.3414.018.45-12.7322.62
Capital Expenditures-----0.152.23-0.01-0.63-1.97
Free Cash Flow6.91-0.986.472.6014.6832.4916.248.44-13.3520.65
Cash & Equivalents5.456.507.487.6411.6734.566.52197323460
Total Debt-------116129134
Net Cash / Debt5.456.507.487.6411.6734.566.5280.89194326
Assets6.4815.519.5111.2722.8935.047.12200343489
Liabilities0.420.520.370.944.805.441.87122146157
Book Value6.0614.999.1410.3318.0929.605.2677.47197332
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enzon Pharmaceuticals, Inc.
Country United States
CEO Andrew D. Rackear

Stock Information

Ticker Symbol ENZN
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ENZN
IPO Date February 15, 1984

Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.